206 related articles for article (PubMed ID: 8682150)
1. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
2. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
[TBL] [Abstract][Full Text] [Related]
3. A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Gröne HJ; Lohmer S; Wohlfeil S
Am J Hum Genet; 1996 Feb; 58(2):281-91. PubMed ID: 8571954
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant.
Feussner G; Albanese M; Valencia A
Atherosclerosis; 1996 Oct; 126(2):177-84. PubMed ID: 8902143
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U
Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.
Wardell MR; Brennan SO; Janus ED; Fraser R; Carrell RW
J Clin Invest; 1987 Aug; 80(2):483-90. PubMed ID: 3038959
[TBL] [Abstract][Full Text] [Related]
11. Apo E variants in patients with type III hyperlipoproteinemia.
Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
[TBL] [Abstract][Full Text] [Related]
12. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia.
Lohse P; Rader DJ; Brewer HB
J Biol Chem; 1992 Jul; 267(19):13642-6. PubMed ID: 1352296
[TBL] [Abstract][Full Text] [Related]
13. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.
Pocovi M; Cenarro A; Civeira F; Myers RH; Casao E; Esteban M; Ordovas JM
Atherosclerosis; 1996 Apr; 122(1):33-46. PubMed ID: 8724110
[TBL] [Abstract][Full Text] [Related]
14. Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping.
Walden CC; Huff MW; Leiter LA; Connelly PW; Hegele RA
J Clin Endocrinol Metab; 1994 Mar; 78(3):699-704. PubMed ID: 7907341
[TBL] [Abstract][Full Text] [Related]
15. Identification of an apolipoprotein(e) variant associated with type III hyperlipoproteinaemia in an indigenous Australian.
Tate JR; Hoffmann MM; Lovelock PK; Kesting JB; Shaw JT
Ann Clin Biochem; 2001 Jan; 38(Pt 1):46-53. PubMed ID: 11270841
[TBL] [Abstract][Full Text] [Related]
16. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
[TBL] [Abstract][Full Text] [Related]
17. Identification, molecular characterization, and cellular studies of an apolipoprotein E mutant (E1) in three unrelated families with hyperlipidemia.
Miller DB; Hegele RA; Wolfe BM; Huff MW
J Clin Endocrinol Metab; 1995 Mar; 80(3):807-13. PubMed ID: 7883834
[TBL] [Abstract][Full Text] [Related]
18. Serum lipids, lipoproteins and apolipoprotein E phenotypes in relatives of patients with type III hyperlipoproteinaemia.
Stuyt PM; Demacker PN; van 't Laar A
Eur J Clin Invest; 1984 Jun; 14(3):219-26. PubMed ID: 6432551
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.
Rall SC; Weisgraber KH; Innerarity TL; Bersot TP; Mahley RW; Blum CB
J Clin Invest; 1983 Oct; 72(4):1288-97. PubMed ID: 6313758
[TBL] [Abstract][Full Text] [Related]
20. Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.
Sakuma N; Hibino T; Saeki T; Nagata T; Sato T; Okuda N; Matsunaga A; Sasaki J
J Atheroscler Thromb; 2014; 21(9):983-8. PubMed ID: 24953047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
